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 i  g  h  l  i  g  h  t  s
We  investigated  the effects  of  Parawixin2  in  kindling  acquisition.
We  used  sub-convulsive  doses  of  PTZ  until  fully  kindled  animals  were  observed.
We  compared  the  effects  of Parawixin2  with  DZP  and  nipecotic  acid.
Repeated  administration  of  Parawixin2  avoids  kindling  acquisition.
GABA  transport  inhibition  by Parawixin2  is  strongly  anticonvulsant.
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a  b  s  t  r  a  c  t
The  aims  of  the  present  work  were  to investigate  the  effects  of  the  repeated  administration  of Parawixin2
(2-amino-5-ureidopentanamide;  formerly  FrPbAII),  a  novel  GABA  and  glycine  uptake  inhibitor,  in  rats
submitted  to  PTZ-induced  kindling.  Wistar  rats  were  randomly  divided  in  groups  (n  = 6–8)  for  different
treatments.  Systemic  injections  of PTZ  were  administered  every  48  h  in  the  dose  of 33  mg/kg;  i.p.,  that
is  sufﬁcient  to  induce  fully  kindled  seizures  in saline  i.c.v.  treated  rats  in  a short  period  of  time  (28
days).  Treatments  in  two  types  of  positive  controls  (diazepam  – DZP  and nipecotic  acid  –  NA  groups)
consisted  in daily  systemic  injections  of  DZP  (2  mg/kg;  i.p.)  or  i.c.v.  injections  of  NA  (12  g/L),  while  in
experimental  groups  in  daily  i.c.v. injections  of  different  doses  of  Parawixin2  (0.15;  0.075; 0.015  g/L).
Seizures  were  analyzed  using  the  Lamberty  &  Klitgaard  score  and  kindling  was  considered  as  established
after  at  least  three  consecutive  seizures  of  score  4  or  5.  Cumulative  seizure  scores  for each  group  werepider  venom analyzed  using  repeated  measures  of  ANOVA  followed  by  Tukey  test.  PTZ  induced  4 and  5-score  seizures
after  12  injections  in  saline  treated  rats,  whereas  daily  injection  of  Parawixin2  inhibited  the  onset  of
seizures  in  a dose  dependent  manner.  Also,  the  challenging  administration  of  PTZ  did  not  raise  seizure
score  in  animals  treated  with  the  highest  dose  of  Parawixin2  or  those  treated  with  DZP  or  NA. These
ﬁndings  together  with  previous  data  from  our  laboratory  show  that  Parawixin2  could  be a  useful  probe
ic  druto  design  new  antiepilept
. IntroductionEpilepsy is a common and chronic neurological disorder that
ffects approximately 1% of the global population [3], which is char-
cterized by recurrent and spontaneous seizure activity [16,24],
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induced by the neuronal hyperactivity in the brain [18]. Kin-
dling is an epilepsy functional model that allows the investigation
of epilepsy-related behavioral, neurophysiological and neuro-
chemical changes without gross morphological damage [18,21].
Kindling phenomenon may  be described as the repeated stimula-
tion of cerebral structures with sub-threshold electric currents or
sub-convulsive doses of chemical convulsants, such as pentylenete-
Open access under the Elsevier OA license.trazole (PTZ), which settle on the appearance and progressive
intensiﬁcation of convulsant activity, culminating in generalized
seizures [12]. Moreover, the development of kindling leads to cel-
lular alterations in speciﬁc brain areas, such as the hippocampus
cience Letters 543 (2013) 12– 16 13
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19] resulting in impairment of learning and memory processes
14].
It has been proposed that kindling-induced epileptogenesis is
ased upon an enhanced activation of glutamatergic pathways,
nd/or attenuated activation in GABAergic pathways [18]. Further-
ore, behavioral and biochemical data have shown that GABAergic
nhibitory activity is reduced in the central nervous system (CNS)
f kindled rats as well as in the brains of humans with many types
f epilepsy [17,18].
In  this context, GABA inhibitory effects may  be enhanced either
y direct activation of GABAergic receptors or by the blockade of
ABA transporters (GATs) present in neuronal and glial membranes
urrounding the synaptic cleft [5,23]. For this reason, GABA uptake
nhibitors have been widely used as pharmacological tools to eluci-
ate many aspects of neural processes in which GABA is involved.
urthermore, potent anticonvulsant effects were attributed to GAT
nhibitors in many animal models of epilepsy, as those drugs pro-
ong the inhibitory GABAergic activity [22,26].
Parawixin2 (2-amino-5-ureidopentanamide; formerly FrPbAII)
as isolated from the venom of the spider Parawixia bistriata in the
earch for novel neuroactive molecules [2]. Parawixin2 is a potent
nticonvulsant and anxiolytic agent with mild side-effects when
dministered intracerebrally in Wistar rats [10,15]. The primary
ode of action of this compound is probably related to the inhibi-
ion of GABA and glycine re-uptakes, as shown with rat cortical and
etina synaptosomes [2]. In terms of GABA neurotransmission and
ccording to Gelfuso et al. [10], Parawixin2 exerts its action prefer-
ntially on GABA transporters GAT1 subtype, although it possibly
cts on other subtypes, but with lower afﬁnity.
Although tested in a variety of acute seizure rat models [10,15],
arawixin2 was not previously studied in chronic models of
pilepsy, and therefore, its efﬁcacy as an antiepileptogenic or a
isease-modifying drug remains to be analyzed. Based on these
acts, the aim of the present work was to evaluate the effects of
arawixin2, a nonselective GABA and glycine uptake inhibitor on
he development of rat kindling in comparison with Diazepam and
ipecotic acid.
.  Materials and methods
.1.  Animals and surgery
Male  Wistar rats (200–250 g) obtained from the central vivar-
um at the University of São Paulo Campus of Ribeirão Preto were
sed in the assays. The animals were kept in pairs in cages under
ontrolled experimental conditions (25 ◦C; 50–60% humidity and a
2-h dark/light cycle with lights on at 7:00 a.m.) with free access
o rat chow and water ad libitum, except during assays.
One  day after arrival, animals were anesthetized with sodium
hiopental 40 mg/kg (Cristalia, Brazil) for stereotaxic implanta-
ion of a stainless steel guide cannula (10 mm)  in the right lateral
entricle. The skull was exposed after a single injection of local
nesthetics (xylocaine 3% with epinephrine 2%) and stereotaxic
oordinates were marked as follows: 0.9 mm posterior to bregma,
.6 mm lateral from midline and 3.4 mm ventral from the surface
f the skull according to the Atlas of Paxinos and Watson [20]. Can-
ulae were ﬁxed to the skulls of animals with dental acrylate and
ere sealed with a stainless steel wires to avoid obstruction. The
nimals were then allowed to rest for 5–7 days to recover from
urgery.
This work was approved by the Ethics Committee for
xperimental Animals at the University Campus (protocol nr:
6.1.91.53.4) that follows the Brazilian Federal Law for Animal
xperimentation (Law nr: 11.794/2008) and American Phys-
ological Society and Ethical Guidelines for investigations ofFig. 1. Chemical structure of Parawixin2 (2-amino-5-ureidopentanamide) isolated
from the Parawixia bistriata spider venom [2].
Experimental Pain in Conscious Animals. Also, every effort was
made to avoid unnecessary stress and pain to the animals.
2.2.  Parawixin2 and drugs
Parawixin2  was  obtained by fractionation of low molecular
weight compounds of P. bistriata venom in HPLC as described in
details by Beleboni et al. [2]. Molecular mass spectral analyses were
performed on a Quattro-LC instrument from Micromass (Manches-
ter, UK) and the primary structure of Parawixin2 was  obtained by
Magnetic Resonance (Fig. 1).
The following drugs and concentrations were used in the
experiments: nipecotic acid (12 g/animal, Sigma–Aldrich, USA)
injected via intracerebroventricular (i.c.v.), diazepam (2 mg/kg,
União Química, Brazil) and pentylenetetrazole (PTZ; 33 mg/kg,
Sigma–Aldrich, USA) both injected via intraperitoneal (i.p.). All
drugs were dissolved in sterile physiological saline (NaCl, 0.9%;
w/v), which was used alone as negative control.
2.3. PTZ-induced kindling
After  recovery from surgery, PTZ administrations were initial-
ized. Animals (n = 6–8, each group) were injected with a single
dose of PTZ (33 mg/kg; i.p.) in every other day, in the morning
period. Immediately after each injection, animals were observed for
30 min. Convulsive behaviors were scored according to Lamberty &
Klitgaard [14] as follows: 0, no response; 1, ear and facial twitch-
ing; 2, myoclonic jerks without rearing; 3, myoclonic jerks with
rearing; 4, turning over into side position, bilateral clonic–tonic
seizures; 5, turning over into back position, generalized clonic and
tonic seizures. Rats received PTZ injections until the observation of
at least three consecutive seizures of score 4 or 5, when they were
considered fully kindled.
Cumulative  kindling score, average of individual behavioral
scores divided by the number of animals, was  plotted against time
in days. The following treatment groups were included in the anal-
ysis:
• Group  1: Saline, i.c.v. (daily for 27 days) + PTZ, i.p. (alternated from
1st  to 27th day).
• Group  2: Diazepam, i.p. (daily for 27 days) + PTZ, i.p. (alternated
from  1st to 27th day).
• Group  3: Nipecotic acid, i.c.v. (daily for 27 days) + PTZ, i.p. (alter-
nated  from 1st to 27th day).
• Groups  4–6: Parawixin2, i.c.v. (each dose – daily for 27
days) + PTZ, i.p. (alternated from 1st to 27th day).
In  the days of PTZ administration, Parawixin2, nipecotic acid and
saline were injected 20 min prior to the convulsant, whereas DZP
were injected 30 min  before the administration of PTZ. One  week
after the last injection of PTZ, another administration of this con-
vulsant was  performed in all rats 15 min  after Parawixin2 (0.037,
0.15 and 0.75 g/L) or nipecotic acid (12 g/L) or 30 min  after
DZP (2 mg/kg). This generally referred to as the challenge dose of
14 E.A. Gelfuso et al. / Neuroscience Letters 543 (2013) 12– 16
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Fig. 2. Cumulative mean seizure score of rats treated with alternate sub-convulsive
doses  of PTZ. Animals were treated with daily injections of (A) PTZ + saline (0.9%;
w/v), PTZ + DZP (2 mg/kg), PTZ + nipecotic acid (12 g/L) and (B) PTZ + Parawixin2
(0.15  g/L), PTZ + Parawixin2 (0.075 g/L), PTZ + Parawixin2 (0.015 g/L). Con-
trol  animals did not receive PTZ injections (vehicle) and were excluded from the
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Fig. 3. Mean area under the curve of each treatment (AUC): (a) PTZ + saline
(150  mM),  (b) PTZ + DZP (2 mg/kg), (c) PTZ + nipecotic acid (12 g/L), (d)
PTZ  + Parawixin2 (0.15 g/L), (e) PTZ + Parawixin2 (0.075 g/L) and (f)
that rats treated with Parawixin2 (0.15 g/L), DZP and nipecotic
acid did not present convulsive seizures [F(5,29) = 41.67; p < 0.001]
(Fig. 4).
Fig. 4. Mean seizure score of rats treated with the challenging administration ofnalysis, but were observed during experimental procedures. Repeated measures
NOVA  followed by Tukey as the post-test considering signiﬁcant (*) p < 0.05, (**)
 < 0.01 and (***) p < 0.001.
he convulsant and it is delivered to animals in order to check the
ermanence of the kindled state.
.4. Statistical analysis
Mean  scores in each group were submitted to repeated meas-
res analysis of variance (ANOVA). In case of signiﬁcant effects of
reatments, one-way ANOVAs followed by Tukey test, at each time
nterval, were performed (SPSS for Windows, version 13.0; USA).
urthermore, areas under the curves (AUCs) were compared using
ne-way ANOVA followed by Tukey test.
. Results
Chronic administration of a sub-convulsive dose of PTZ
33 mg/kg, i.p.) on alternate days for a period of 27 days
rogressively increased seizures score, producing kindling in
TZ + saline-treated rats (Fig. 2A and B). In this case, the ﬁrst
yoclonic jerks (score 2 seizures) were observed after the 3rd
dministration, and kindling criteria were reached after 12 injec-
ions. DZP, nipecotic acid and the highest dose of the Parawixin2
0.15 g/L) suppressed the progression of PTZ kindling (Fig. 2A
nd B). Statistical analyses revealed signiﬁcant effects of treatment
F(5,9) = 21.083; p < 0.001], number of injections [F(13,17) = 22.765;
 < 0.0001], and treatment-versus-number of injections interaction
F(65,77) = 3.328; p < 0.001]. One-way ANOVA analyses showed a
igniﬁcant effect of treatments in all analyzed periods [F(5,29) vary-
ng from 2.715 to 30.296; p < 0.05]. Post hoc analysis indicated
hat rats treated with Parawixin2 (0.15 g/L), DZP and nipecotic
cid had lower seizure score in all assessed periods as compared
ith PTZ + saline injected group and the lowest dose of Parawixin2
0.015 g/L) (p < 0.05).PTZ  + Parawixin2 (0.015 g/L). AUCs were calculated for each animal and then
analyzed  by one-way ANOVA followed by Tukey test, considering (*) p < 0.05, (**)
p < 0.01 and (***) p < 0.001.
Daily administration of Parawixin2 induced a dose-dependent
anticonvulsant effect. In this regard, signiﬁcant differences
between PTZ + saline group and the highest dose of Parawixin2
were observed at the 6th day of PTZ administration, whereas rats
treated with the intermediate dose of Parawixin2 (0.075 g/L)
exhibited lower seizure score after 8–13th PTZ injections (p < 0.05).
Similar results were found for both nipecotic acid and DZP,
decreasing seizure score at the 6th PTZ injection and at 7th injec-
tion, respectively. Also, at the 8th injection of PTZ, seizure mean
score of rats treated with nipecotic acid, DZP, 0.015 and 0.075 g/L
Parawixin2 were reduced (p < 0.05).
The  analysis of AUCs of all treatments revealed that ani-
mals pre-treated with Parawixin2 (0.15 g/L), DZP or nipecotic
acid had signiﬁcantly lower AUCs then PTZ + saline injected ani-
mals or the lowest dose of Parawixin2 [F(5,29) = 20.23; p < 0.001]
(Fig. 3).
Finally, the analysis of mean seizure score of rats after the chal-
lenge administration of PTZ before anticonvulsant administration
showed that none of the two lower doses of Parawixin2 (0.075
and 0.015 g/L) inhibited seizure onset. In contrast, we observedPTZ sub-convulsive dose. Animals were treated with (a) PTZ + saline (150 mM),
(b)  PTZ + DZP (2 mg/kg), (c) PTZ + nipecotic acid (12 g/L), (d) PTZ + Parawixin2
(0.15  g/L), (e) PTZ + Parawixin2 (0.075 g/L) and (f) PTZ + Parawixin2
(0.015 g/L). Data were analyzed by one way ANOVA followed by Tukey as the
post-test  considering signiﬁcant (**) p < 0.01 and (***) p < 0.001.
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. Discussion
We  have identiﬁed Parawixin2, from the venom of the spi-
er P. bistriata, which inhibits both GABA and glycine uptakes in
ynaptosomes from rat cerebral cortices and retina [2]. Previous
orks showed that i.c.v. administration of Parawixin2 induced
arked anticonvulsant effects against several models of chemically
nduced acute seizures [10,15]. In this work we have analyzed the
ffects of chronic administration of Parawixin2 in the progression
f PTZ-induced kindling, and we demonstrated that Parawixin2
ffectively blocked behavioral expression of these seizures.
Development of PTZ-induced kindling appears to involve
hanges in inhibitory transmission as previous studies show strong
ssociation of seizures with loss of GABAergic neurons and decrease
n the number of GABAA receptor binding sites [8,13]. GABAA recep-
or agonists phenobarbital and DZP suppress the development
f kindling, whereas the effects of GABAB receptor agonists are
ependent on age and dose [25]. Paradoxically, the blockade of
ABAB receptor, delays the onset of seizures and ameliorate cogni-
ive and memory impairments followed by PTZ kindling [11].
To  date, four subtypes of GATs have been cloned, GAT 1–4, of
hich GAT-1 is the most predominant in brain neurons [4]. The
xpression of transporter subtypes has been investigated. Accord-
ng to Dalby and Nielsen [7], GABA transporters may  exert different
oles in the kindling-induced epileptogenesis. Speciﬁc inhibitors of
AT-1, such as tiagabine and nipecotic acid suppress seizures of ani-
als submitted to focal kindling, secondarily generalized seizures
nd clonic seizures, but they are ineffective against tonic convul-
ions induced by electroshock [7]. Conversely, GAT non-speciﬁc
nhibitors block convulsions induced by electroshock, but they are
neffective against clonic convulsions induced by chemical convul-
ants and their effectiveness in focal kindling seizures is apparently
roportional to the ratio between afﬁnities for GAT-1/GAT-3 [6].
The effects of Parawixin2 on kindling progression could be
ttributed to the blockade of GABAergic transporters, which is
hought to be the main mode of action of Parawixin2 [2]. The
lockade of GABA transporters may  lead to an increase in the con-
entration of the released GABA in the synaptic cleft and thus, a
rolonged inhibitory effect. The advantage of using GABA trans-
ort inhibitors as a therapeutic strategy is that these agents may
ause less untoward side-effects, since they act on a concentration
f GABA released under physiological conditions [1,9].
In  order to compare the effectiveness of Parawixin2, we  chose to
se two drugs that enhance GABAergic inhibitory effects, diazepam
nd nipecotic acid. In this regard, we showed that Parawixin2
locked seizure progression in 100% of rats treated with 0.15 g/L,
pproximately 0.14 nmol, whereas the dose of nipecotic acid
eeded was 12 g/L, approximately 46.5 nmol a far higher dose.
his difference in efﬁciency was previously reported by Liber-
to et al. [15] in rats submitted to limbic seizures elicited by the
ABAergic blockade of the Area tempestas in the deep pyriform
ortex. According to these authors the microinjection of nipecotic
cid into the Substantia nigra pars reticulata does not suppress lim-
ic seizures elicited by the microinjection of GABA antagonists
nto the A. tempestas. In contrast, Parawixin2 efﬁciently blocks
hese seizures. Moreover, Parawixin2 blocks chemically induced
eizures, whereas, non-speciﬁc GABA transport inhibitors fail [10].
he present ﬁndings, together with previous data, might cor-
oborate with the initial hypothesis of a non-selective action of
arawixin2 over GABA transporters, although it might preferen-
ially block GAT1 subtype. Therefore, our main hypothesis is that,
ince our administration of Parawixin2 was performed in via i.c.v.
nd GAT1 subtype is widely expressed in the limbic structures that
enerate kindling behaviors, our molecule is preferentially block-
ng these types of transporters and increasing GABA concentration
n the synaptic cleft. Another point is the action of Parawixin2 on
[ Letters 543 (2013) 12– 16 15
glycine  transporters [2]. Since Parawixin2 is also a glycine uptake
inhibitor [2] and glycine is recognized as an important inhibitory
neurotransmitter, an implication of glycine uptake inhibition on
anticonvulsant effects of Parawixin2 cannot be excluded here.
To  our knowledge there are no reports on drugs with these
modes of action, leaving Parawixin2 as a unique compound with
in vivo activity as anticonvulsant with potential disease modifying
effects.
5. Conclusion
In this work we showed that Parawixin2 is an alternative tool
that can be used as a probe to design novel therapeutic agents, since
it blocks the establishment of kindling phenomenon. In this same
context, we conclude that the blockade of GABA transporters may
represent a rational strategy to prevent neuronal disorders which
involve alterations in GABAergic function.
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